|Bid||85.14 x 900|
|Ask||85.15 x 2200|
|Day's range||84.81 - 85.62|
|52-week range||79.34 - 95.17|
|Beta (5Y monthly)||0.53|
|PE ratio (TTM)||19.69|
|Forward dividend & yield||3.20 (3.66%)|
|Ex-dividend date||04 Mar 2021|
|1y target est||101.20|
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Cintia Piccina as Chief Commercial Officer effective January 31, 2022. “I am delighted to welcome Cintia to our leadership team. She brings extensive commercial experience, including in cell and gene therapy, that will be key as we prepare to submit our first BLA for afami-cel this year, and buil
The FDA bestows an Orphan Drug status to Ionis' (IONS) investigational medicine, eplontersen, for treating people living with transthyretin-mediated amyloidosis.
Novartis and Molecular Partners reported positive results for COVID-19 candidate ensovibep.